In re Accutane Litig., 2017 WL 3138003 (App. Div. July 25, 2017).  [Disclosure:  I argued for the successful plaintiffs in one of these two consolidated appeals, the one that involved the NJPLA.]  The New Jersey Product Liability Act, N.J.S.A. 2A:58C-4 (“NJPLA”), creates a presumption, which the Supreme Court has labeled a “virtually dispositive” “super-presumption,” that a manufacturer’s warning regarding a drug is adequate if that warning has been approved by the federal Food and Drug Administration.  The Supreme Court and the Appella

July 21, 1983 saw two very important opinions from the Supreme Court.  One of them, Application of Matthews, 94 N.J. 59 (1983), was the first major opinion regarding a Committee on Character issue.  That case was discussed, indirectly, here.

The other decision, State v. Ventron, 94 N.J. 473 (1983), was and still is the leading New Jersey case regarding the criteria for piercing the corporate veil.  The case involved liability for pollution.  The lower courts

North Jersey Media Group, Inc. v. Lyndhurst Tp., ___ N.J. ___ (2017).  Due to the amount of administrative duties that attend the office of Chief Justice of the Supreme Court of New Jersey, Chief Justices traditionally have not authored as many opinions as Associate Justices do.  But when Chief Justices write, it is often an unusually important decision and/or one with significant public policy overtones.  This decision by Chief Justice Rabner, for a unanimous